732 related articles for article (PubMed ID: 26920914)
1. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
[TBL] [Abstract][Full Text] [Related]
2. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
[TBL] [Abstract][Full Text] [Related]
3. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Gillard M
Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
[TBL] [Abstract][Full Text] [Related]
4. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.
Russo E; Citraro R; Mula M
Expert Opin Drug Discov; 2017 Nov; 12(11):1169-1178. PubMed ID: 28829199
[TBL] [Abstract][Full Text] [Related]
5. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.
Gillard M; Fuks B; Leclercq K; Matagne A
Eur J Pharmacol; 2011 Aug; 664(1-3):36-44. PubMed ID: 21575627
[TBL] [Abstract][Full Text] [Related]
6. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Sands ZA; Vandenplas C; Gillard M
Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
[TBL] [Abstract][Full Text] [Related]
7. Brivaracetam for the treatment of epilepsy.
Schulze-Bonhage A
Expert Opin Pharmacother; 2011 Aug; 12(12):1959-66. PubMed ID: 21682662
[TBL] [Abstract][Full Text] [Related]
8. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
[TBL] [Abstract][Full Text] [Related]
9. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.
Mumoli L; Palleria C; Gasparini S; Citraro R; Labate A; Ferlazzo E; Gambardella A; De Sarro G; Russo E
Drug Des Devel Ther; 2015; 9():5719-25. PubMed ID: 26543353
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
Asadi-Pooya AA; Sperling MR; Chung S; Klein P; Diaz A; Elmoufti S; Schiemann J; Whitesides J
Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
[TBL] [Abstract][Full Text] [Related]
11. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons.
Niespodziany I; Rigo JM; Moonen G; Matagne A; Klitgaard H; Wolff C
Epilepsia; 2017 Nov; 58(11):e157-e161. PubMed ID: 28850675
[TBL] [Abstract][Full Text] [Related]
12. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
[TBL] [Abstract][Full Text] [Related]
13. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy.
Klein P; Bourikas D
Adv Ther; 2024 Jul; 41(7):2682-2699. PubMed ID: 38811492
[TBL] [Abstract][Full Text] [Related]
14. Brivaracetam augments short-term depression and slows vesicle recycling.
Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
[TBL] [Abstract][Full Text] [Related]
15. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.
Biton V; Berkovic SF; Abou-Khalil B; Sperling MR; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):57-66. PubMed ID: 24446953
[TBL] [Abstract][Full Text] [Related]
16. Brivaracetam efficacy and safety in focal epilepsy.
Makke Y; Abou-Khalil B
Expert Rev Neurother; 2019 Oct; 19(10):955-964. PubMed ID: 31195850
[No Abstract] [Full Text] [Related]
17. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.
Yamagata A; Ito K; Suzuki T; Dohmae N; Terada T; Shirouzu M
Nat Commun; 2024 Apr; 15(1):3027. PubMed ID: 38637505
[TBL] [Abstract][Full Text] [Related]
18. Brivaracetam in the treatment of epilepsy: a review of clinical trial data.
Feyissa AM
Neuropsychiatr Dis Treat; 2019; 15():2587-2600. PubMed ID: 31571877
[TBL] [Abstract][Full Text] [Related]
19. [Brivaracetam in the treatment of patients with epilepsy].
Karlov VA; Vlasov PN; Zhidkova IA; Kissin MY; Lebedeva AV; Lipatova LV; Mkrtchyan VR; Mukhin KY; Rudakova IG
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(9. Vyp. 2):55-62. PubMed ID: 29213040
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
Kwan P; Trinka E; Van Paesschen W; Rektor I; Johnson ME; Lu S
Epilepsia; 2014 Jan; 55(1):38-46. PubMed ID: 24116853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
